16.30

4.51% -0.77

After Hours: 16.30

Anika Therapeutics Inc (ANIK)

Overview News Price History Option Chain Financials Discussions Forecast

Anika Therapeutics Inc stock is traded at $16.30, with a volume of 222.41K. It is down -4.51% in the last 24 hours and down -34.77% over the past month. Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States.

Previous Close:

$17.07

Open:

$17.17

24h Volume:

222.41K

Relative Volume:

3.59

Market Cap:

$243.48M

Revenue:

$166.88M

Net Income/Loss:

$-74.18M

P/E Ratio:

-10.65

EPS:

-1.53

Net Cash Flow:

$1.14M

1W Performance:

-33.52%

1M Performance:

-34.77%

6M Performance:

-40.92%

1Y Performance:

-22.82%

1-Day Range:

$16.15

$17.24

1-Week Range:

$16.00

$24.84

52-Week Range:

$16.00

$29.11

Anika Therapeutics Inc Stock (ANIK) Company Profile

Name

Anika Therapeutics Inc

Sector

Healthcare (1182)

Industry

Drug Manufacturers - Specialty & Generic (85)

Phone

(781) 457-9000

Address

32 WIGGINS AVENUE, BEDFORD, MA

Employee

357

Twitter

Next Earnings Date

2024-10-31

Latest SEC Filings

ANIK's Discussions on Twitter

Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-14-23	Upgrade	Barrington Research	Mkt Perform → Outperform
Mar-07-23	Downgrade	Barrington Research	Outperform → Mkt Perform
Nov-09-22	Upgrade	Barrington Research	Mkt Perform → Outperform
Oct-14-22	Resumed	Stephens	Equal-Weight
Mar-09-22	Downgrade	Barrington Research	Outperform → Mkt Perform
Mar-09-22	Downgrade	Stephens	Overweight → Equal-Weight
Nov-16-21	Initiated	Stephens	Overweight
Jul-16-21	Initiated	UBS	Neutral
Dec-16-20	Upgrade	Barrington Research	Mkt Perform → Outperform
May-08-20	Downgrade	Barrington Research	Outperform → Mkt Perform
Jan-21-20	Upgrade	Sidoti	Neutral → Buy
Jan-10-20	Upgrade	First Analysis Sec	Outperform → Strong Buy
Nov-05-19	Initiated	BWS Financial	Sell
Sep-24-19	Reiterated	Barrington Research	Outperform
Sep-23-19	Downgrade	First Analysis Sec	Strong Buy → Outperform
Jul-25-19	Upgrade	First Analysis Sec	Neutral → Strong Buy
Feb-22-19	Downgrade	First Analysis Sec	Outperform → Neutral
Feb-22-19	Downgrade	Sidoti	Buy → Neutral
Jul-27-18	Upgrade	Barrington Research	Mkt Perform → Outperform
Jun-20-18	Downgrade	Barrington Research	Outperform → Mkt Perform
Jun-20-18	Downgrade	First Analysis Sec	Overweight → Equal-Weight
May-04-18	Upgrade	Barrington Research	Mkt Perform → Outperform
Feb-23-18	Downgrade	Barrington Research	Outperform → Mkt Perform
Jan-24-18	Upgrade	First Analysis Sec	Equal-Weight → Overweight
Oct-27-17	Reiterated	Barrington Research	Outperform
May-09-16	Upgrade	Singular Research	BUY - Long-Term → Buy
Apr-27-16	Downgrade	Northland Capital	Outperform → Market Perform
Feb-26-16	Reiterated	Barrington Research	Outperform

View All

Anika Therapeutics Inc Stock (ANIK) Latest News

09:23 AM

Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Sold by Capital Management Corp VA - MarketBeat

09:23 AM

04:37 AM

Viscosupplementation Market Report Analysis, Growth - openPR

04:37 AM

Nov 04, 2024

Anika Therapeutics (NASDAQ:ANIK) Downgraded to Hold Rating by StockNews.com - MarketBeat

Nov 04, 2024

Anika Therapeutics, Inc. (NASDAQ:ANIK) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 04, 2024

Barrington Research Cuts Anika Therapeutics (NASDAQ:ANIK) Price Target to $25.00 - Defense World

Nov 04, 2024

Nov 03, 2024

Earnings call: Anika Therapeutics Focuses on HA Products Amid Restructuring By Investing.com - Investing.com South Africa

Nov 03, 2024

Earnings call: Anika Therapeutics Focuses on HA Products Amid Restructuring - Investing.com

Nov 03, 2024

Nov 02, 2024

Anika Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St

Nov 02, 2024

Anika Therapeutics (ANIK) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 02, 2024

Nov 01, 2024

Barrington Research Issues Pessimistic Forecast for Anika Therapeutics (NASDAQ:ANIK) Stock Price - MarketBeat

Nov 01, 2024

Anika Therapeutics (NASDAQ:ANIK shareholders incur further losses as stock declines 30% this week, taking five-year losses to 72% - Simply Wall St

Nov 01, 2024

Anika: Q3 Earnings Snapshot - New Haven Register

Nov 01, 2024